Future microbiology
-
Future microbiology · Jan 2015
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. ⋯ Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.
-
Future microbiology · Jan 2015
ReviewSystematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease.
The gut microbiota is modulated by metabolic derangements, such as nutrition overload and obesity. ⋯ Although probiotics and prebiotics have been proposed in the treatment and prevention of patients with obesity-related NAFLD, their therapeutic use is not supported by high-quality clinical studies.
-
Future microbiology · Jan 2015
ReviewClinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
The first clinical Phase III trial evaluating a malaria vaccine was completed in December 2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses data of Phase I-III trials including malaria-naive adults and adults, children and infants from malaria endemic settings in sub-Saharan Africa. ⋯ The RTS,S/AS01 malaria vaccine may become available on the market in the coming year. If so, further strategies should address challenges on how to optimize vaccine efficacy and implementation of RTS,S/AS01 vaccine within the framework of established malaria control measures.
-
Future microbiology · Jan 2015
Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains.
This study aimed to evaluate the antimicrobial activity of two different formulations of bioglass BAG-S53P4 against multiresistant microorganisms involved in bone infections, and the capability of bioglass to select for resistance. ⋯ BAG-S53P4 has a significant potential as bone substitute for the treatment of infections caused by multiresistant microorganisms.
-
Future microbiology · Jan 2015
Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.
The aim was to assess the distribution of nontuberculous mycobacteria (NTM) in treated patients with pulmonary disease (PD) in Greece. ⋯ The increasing number of NTM PD in Greece is a consequence of their isolation being more frequently considered as clinically relevant.